ArticleSensors (Basel, Switzerland)2022
Development and Optimization of Hybrid Polymeric Nanoparticles of Apigenin: Physicochemical Characterization, Antioxidant Activity and Cytotoxicity Evaluation.
Article in Sensors (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Nanotechnology revolutionizing antimicrobial therapy for superbug infections.Discover nano · 2026Review
- Plant-Derived Compounds as Potential Sensitizers to Immunotherapy in Melanoma.International journal of molecular sciences · 2026Review
- Comparison of Selected Pro-Health Biologically Active Chemical Compounds inMolecules (Basel, Switzerland) · 2026Article
- Anticancer activity of an apigenin-functionalized silica-coated silver oxide nanocomposite against human gastric adenocarcinoma cells (AGS): in vitro and in silico analysis.BMC biotechnology · 2026Article
- Data-Driven Optimization of Polyphenol Recovery and Antioxidant Capacity from Medicinal Herbs Using Chemometrics and HPLC Profiling for Functional Food Applications.International journal of molecular sciences · 2025Article
- Liposome integrated hydrogel for diabetic wound healing: molecular mechanisms in inflammation and oxidative stress mitigation.Inflammopharmacology · 2025Article
- Research Progress and Prospects of Flavonoids in the Treatment of Hyperlipidemia: A Narrative Review.Molecules (Basel, Switzerland) · 2025Review
- Lipid-polymer hybrid nanoparticles: a cutting-edge frontier in breast cancer treatment strategies.Nanomedicine (London, England) · 2025Review
- Phytochemical Analysis, Antioxidant and Antibacterial Activities, Minerals Element Profiling, and Identification of Bioactive Compounds by UPLC-HRMS Orbitrap in Four Aromatic and Medicinal Plants.Molecules (Basel, Switzerland) · 2025Article
- QbD-Anchored Preparation and Assessment of Transethosomal Gel for Enhanced Skin Permeation of Tamoxifen Citrate.Current pharmaceutical design · 2025Article
- TPGS-modified Chitosan Nanoparticles of EGFR Inhibitor: Physicochemical andCurrent drug delivery · 2025Article
- Phytoactive Molecules and Nanodelivery Approaches for Breast Cancer Treatment: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigenin.Therapeutic delivery · 2024Review
- A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms.Food science & nutrition · 2023Review
- Trends in Photothermal Nanostructures for Antimicrobial Applications.International journal of molecular sciences · 2023Review
- Article
- Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives.Biomedicines · 2023Review
- RETRACTED: Design and Evaluation of Solid Lipid Nanoparticles Loaded Topical Gels: Repurpose of Fluoxetine in Diabetic Wound Healing.Gels (Basel, Switzerland) · 2022Article
- Formulation and Evaluation of Apigenin-Loaded Hybrid Nanoparticles.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Breast cancer is the most common cancer in females and ranked second after skin cancer. The use of natural compounds is a good alternative for the treatment of breast cancer with less toxicity than synthetic drugs. The aim of the present study is to develop and characterize hybrid Apigenin (AN) Nanoparticles (NPs) for oral delivery (AN-NPs). The hybrid AN-NPs were prepared by the self-assembly method using lecithin, chitosan and TPGS. Further, the NPs were optimized by Box-Behnken design (3-factor, 3-level). The hybrid NPs were evaluated for particle size (PS), entrapment efficiency (EE), zeta potential (ZP), and drug release. The optimized hybrid NPs (ON2), were further evaluated for solid state characterization, permeation, antioxidant, cytotoxicity and antimicrobial study. The formulation (ON2) exhibited small PS of 192.6 ± 4.2 nm, high EE 69.35 ± 1.1%, zeta potential of +36.54 mV, and sustained drug release (61.5 ± 2.5% in 24 h), as well as significantly (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.